bannerHON
img
HONnews
HONnews
img PATIENT / PARTICULIER img PROFESSIONNEL DE SANTE img WEBMESTRE img
img
 
img
HONcode sites
All Web sites
HONselect
News
Conferences
Images

Themes:
A B C D E F G H I
J K L M N O P Q
R S T U V W X Y Z
Browse archive:
2014: J J M A M F J
2013: D N O S A J

  Pros, Cons to Dissolving Lung Clots: Study
Clot-busting drugs appear to save lives but increase risk of serious bleeding

By Steven Reinberg
HealthDay Reporter

TUESDAY, June 17, 2014 (HealthDay News) -- Drugs used to break up blood clots in the lungs may lower the risk of death, but they also increase the risk of bleeding, a new study finds.

Researchers analyzed data from 16 trials involving use of clot-busting drugs called thrombolytics to treat life-threatening clots in the lungs (pulmonary embolism).

Despite the drugs' apparent life-saving benefits, the risk of major bleeding, particularly in the brain, remains a concern, experts say.

"The study advances our understanding, but is not enough to provide a definitive recommendation for use in all patients," said Dr. Joshua Beckman, director of the cardiovascular fellowship program at Brigham and Women's Hospital in Boston, who was not involved in the study.

The evidence suggests that clot-busting therapy has merit but needs more study to refine the method by which it is given and to whom, added Beckman.

What's important, said lead study author Dr. Jay Giri, is "we discovered that thrombolytic therapy was associated with a death benefit in intermediate-risk pulmonary embolism."

This is a hotly debated topic, Giri said, "and no prior study has had the statistical power to demonstrate this finding.

"Of course," he added, "this potential benefit must be balanced against potential bleeding risks in the individual patient."

The research suggests patients younger than 65 might be at less risk for bleeding from clot-busting drugs, said Giri, an assistant professor of clinical medicine at the University of Pennsylvania in Philadelphia.

A pulmonary embolism is usually treated with blood thinners that prevent clotting or drugs that dissolve clots.

The current study, published in the June 18 issue of the Journal of the American Medical Association, is called a meta-analysis. In this type of study, researchers attempt to find common threads across multiple studies. The weakness of this method is that it relies on data in studies not necessarily designed to draw the conclusions the researchers are looking for.

For Beckman, author of an editorial accompanying the study, this is a key point.

"Moreover, the study shows that the care of patients with pulmonary embolism -- with or without the clot-busting medications -- has gotten much better," he said.

"The rate of death has decreased significantly over the more than four decades of studies included, making it harder to show a benefit of clot-busting therapy in the most recent studies," Beckman said.

He'd like to see how clot-busters compare to newer blood thinners, he said. Also, it's still not clear if the drugs should be delivered intravenously or by catheter directly to the lungs, he noted.

Whether only younger patients should receive thrombolytics is another question for future study, Beckman said.

For the current study, Giri's team analyzed data from studies published over 45 years that included 2,115 patients in all.

The investigators found that clot-dissolving drugs reduced the relative risk of dying early by 47 percent. Among those given these drugs, 2.2 percent died, compared with 3.9 percent of those not receiving clot-busting therapy.

But the risk of major bleeding was nearly tripled with clot-busting drugs compared with drugs used to prevent clotting -- 9.2 percent versus 3.4 percent, the researchers found. Major bleeding was not significantly increased in patients 65 and younger, the authors noted.

Those receiving the clot-busting therapy were also more likely to suffer brain bleeding than those given anti-clotting drugs (1.5 percent versus 0.2 percent). But they were less likely to have another clot in the lung (1.2 percent versus 3 percent), the study found.

Each year pulmonary embolism contributes to almost 30,000 U.S. deaths. Risk of death is heightened for up to three months after the clot occurs, the researchers said.

More information

For more about pulmonary embolism, visit the U.S. National Library of Medicine.

SOURCES: Jay Giri, M.D., M.P.H., assistant professor, clinical medicine, University of Pennsylvania, Philadelphia; Joshua Beckman, M.D., director, Cardiovascular Fellowship Program, Brigham and Women's Hospital, Boston; June 18, 2014, Journal of the American Medical Association

Copyright © 2014 HealthDay. All rights reserved. URL:http://consumer.healthday.com/Article.asp?AID=688929

Resources from HONselect: HONselect is the HON's medical search engine. It retrieves scientific articles, images, conferences and web sites on the selected subject.
Specialty Chemicals and Products
Lung
Risk
Hemorrhage
Research Personnel
Pulmonary Embolism
Embolism
Death
Blood
Association
Brain
The list of medical terms above are retrieved automatically from the article.

Disclaimer: The text presented on this page is not a substitute for professional medical advice. It is for your information only and may not represent your true individual medical situation. Do not hesitate to consult your healthcare provider if you have any questions or concerns. Do not use this information to diagnose or treat a health problem or disease without consulting a qualified healthcare professional.
Be advised that HealthDay articles are derived from various sources and may not reflect your own country regulations. The Health On the Net Foundation does not endorse opinions, products, or services that may appear in HealthDay articles.


Home img About us img MediaCorner img HON newsletter img Site map img Ethical policies img Contact